YUMAB GmbH
ブース番号: C-18-2
www.yumab.com
当社について
YUMAB is a biotechnology company founded in 2012 and has become a world leading provider for the development of fully human, therapeutic antibodies.
YUMAB offers outstanding expertise from more than 30 years of continuous research in recombinant antibody technologies in combination with state of the art and next generation technologies. This unique setting enables novel solutions for current and future challenges in antibody immunotherapy.
The success of next generation antibody drug development relies on comprehensive discovery technologies and strategies.
YUMAB bridges the gap between research innovation and novel therapies. Our advanced discovery platform provides access to challenging targets, enables new formats, and accelerates the development of human antibodies at a high success rate.
From target discovery to fully characterized lead – our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner.
住所
Inhoffenstr. 7
38124 Braunschweig
Germany
電話: +49 5314 811700
連絡担当者:
Alexander Ehm
メール: a.ehm@yumab.com
電話: +49 1702 800357
製品
- Fast track discovery of fully human antibodies
- Immune or patient derived libraries (also from transgenic animals)
- Antibody lead development (IgG, Fab, scFv, bispecifics, CAR, ADC, ...)
- Antibody engineering (affinity, stability, manufacturability)
- In silico lead optimization
- Hybridoma sequencing
- Humanization, Superhumanization
- Contract research and development
- Partnered development
YUMAB® Antibody Discovery
YUMAB® Antibody Engineering
- in-vitro evolution by YUlight shuffling
- in-vitro evolution by mutagenesis
Additionally, in-silico analysis can be applied to identify and optimize antibodies with the best developability score.
- in-silico analysis and optimization
YUMAB® Antibody Humanization
- Germline-optimized CDR grafting
- Template-driven chain shuffling
